Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02137226
Registration number
NCT02137226
Ethics application status
Date submitted
12/05/2014
Date registered
13/05/2014
Date last updated
19/01/2018
Titles & IDs
Public title
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Query!
Scientific title
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Query!
Secondary ID [1]
0
0
2012-002945-40
Query!
Secondary ID [2]
0
0
1297.2
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BI 695501
Treatment: Drugs - US-licensed Humira®
Experimental: BI 695501 - one injection every 2 weeks for 48 weeks (25 injections in total)
Active comparator: US-licensed Humira® - one injection every 2 weeks for 48 weeks (25 injections in total)
Treatment: Drugs: BI 695501
BI 695501, every two weeks for 48 weeks (25 injections in total)
Treatment: Drugs: US-licensed Humira®
one injection every 2 weeks for 48 weeks (25 injections in total)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Proportion of Patients Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 12
Query!
Assessment method [1]
0
0
The proportion of patients meeting the ACR20 response criteria was assessed. A patient had an ACR20 response if all of the following occurred: A = 20 % improvement in the swollen joint count (66 joints), A = 20 % improvement in the tender joint count (68 joints), A = 20 % improvement in at least three of the following assessments: Patient's assessment of pain, Patient's global assessment of disease activity (equivalent to the General Health component of the Disease Activity Score (DAS)), Physician's global assessment of disease activity, Patient's assessment of physical function, as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI) Acute phase reactant (C-reactive protein (CRP)).The Full Analysis Set contained all enrolled patients who were randomized to trial drug and who received at least one dose of trial drug and had all efficacy measures relevant for the co-primary efficacy endpoints measured at baseline and at least once post- baseline.
Query!
Timepoint [1]
0
0
Week 12
Query!
Primary outcome [2]
0
0
The Proportion of Patients Meeting ACR20 Response Criteria at Week 24
Query!
Assessment method [2]
0
0
ACR20 at Week 12 and Week 24 are standard outcome criteria that are widely accepted for regulatory purposes to demonstrate efficacy in treating the signs and symptoms of Rheumatoid arthritis (RA). The proportion of patients meeting the ACR20 response criteria was assessed at Week 12 and Week 24 to provide a robust comparison with US-licensed Humira® data. A patient had an ACR20 response if all of the following occurred: A = 20 % improvement in the swollen joint count (66 joints), A = 20 % improvement in the tender joint count (68 joints), A = 20 % improvement in at least three of the following assessments: Patient's assessment of pain, Patient's global assessment of disease activity (equivalent to the General Health component of the Disease Activity Score (\[DAS\]), Physician's global assessment of disease activity, Patient's assessment of physical function, as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI) Acute phase reactant (C-reactive protein \[CRP\]).
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Change From Baseline in Disease Activity Score 28 (DAS28) (Erythrocyte Sedimentation Rate [ESR]) at Week 12 and Week 24
Query!
Assessment method [1]
0
0
The DAS28 (ESR) score was derived using the following formulae:
DAS28 (ESR) = 0.56\*v(TJC28) + 0.28\*v(SJC28) + 0.014\*(GH) + 0.7\*ln(ESR)
Where:
* TJC28 = 28 joint count for tenderness
* SJC28 = 28 joint count for swelling
* Ln (ESR) = natural logarithm of ESR
* GH = General Health component of the DAS (patient's global assessment of disease activity). DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. Actual number of patient analysed (N) is mean number of subjects in the analysis set with DAS28(ESR) results computable across the multiply imputed data sets. It is 319.6, 317.1 for week 12 and 313.9, 315.1 for week 24 for BI 695501 and US-licensed Humira® respectively.
Query!
Timepoint [1]
0
0
Baseline, Week 12 and Week 24
Query!
Secondary outcome [2]
0
0
The Percentage of Patients With Investigator-assessed Drug-related Adverse Events (AEs) During the Treatment Phase
Query!
Assessment method [2]
0
0
The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). Thus, all AEs with an onset after the first dose of trial drug up to a period of ten weeks after the last dose of trial drug were assigned to the current treatment for evaluation. Investigator-assessed drug related AEs were AEs with a relationship to drug ticked "yes" according to the Investigator. Overall results are presented from Day 1 up to Week 58 and are based on the initial randomization groups. The comparison therefore focuses on patients who received BI 695501 continuously versus patients who received Humira® continuously for the long term assessment of safety. One patient was initially treated with Humira and discontinued prior to Week 24. This patient was mistakenly re randomized to BI 695501 but not treated. For safety this was counted in Humira not re-randomized group (as treated), and for other analysis sets, this patient was counted in the Humira to BI 695501 group (as randomized).
Query!
Timepoint [2]
0
0
From the first drug administration until 10 weeks after the last drug administration, up to 58 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* All patients must sign and date an Informed Consent Form consistent with International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines and local legislation prior to participation in the trial (i.e. prior to any trial procedures, which include medication washout and restrictions) and be willing to follow the protocol.
* Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active Rheumatoid arthritis for at least 6 months as defined by at least six swollen joints (66 joint count) and at least six tender joints (68 joint count) at Screening and Baseline (Day 1), and either an Erythrocyte sedimentation rate of >28 mm/hour OR a C-reactive protein (CRP) level >1.0 mg/dL (normal: <0.4 mg/dL) at Screening. Patients must currently be receiving methotrexate (MTX) therapy.
* Current treatment for Rheumatoid arthritis on an outpatient basis:
1. Must be receiving and tolerating oral or parenteral MTX therapy at a dose of 15 to 25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1. The dose and administration route should remain stable for at least 4 weeks prior to Day 1 until Week 24. After Week 24 the administration route can be changed at the investigator's discretion. Patients receiving a lower dose of MTX (10 to 14 mg/week) should be doing so as a result of a documented history of intolerance to higher doses of MTX.
2. Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or folinic acid (at least 1 mg/week or as per local practice) or equivalent during the entire trial (mandatory comedication for MTX treatment).
3. Disease modifying antirheumatic drug (DMARD) use will be restricted according to guidelines listed in the trial protocol.
4. If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.
5. Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.
6. Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day. These doses must have been stable for a minimum of 12 weeks prior to Day 1. The hydroxychloroquine or chloroquine treatment will need to be continued at a stable dose with the same formulation until the end of the trial.
* For participants of reproductive potential (males and females), a reliable means of contraception has to be used throughout trial participation(acceptable methods of birth control include for example birth control pills, intrauterine devices [IUDs], surgical sterilization, vasectomized partner and double barrier method.. All patients (males and females of child-bearing potential) must also agree to use an acceptable method of contraception for 6 months following completion or discontinuation from the trial medication.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* ACR functional Class IV or wheelchair/bed bound.
* Primary or secondary immunodeficiency, including known history of HIV infection, or a positive test at Screening.
* History of Tuberculosis, latent Tuberculosis, or positive purified protein derivative test or interferon gamma-releasing assay .
* Known clinically significant coronary artery disease or significant cardiac arrhythmias or severe congestive heart failure, or interstitial lung disease.
* Previous treatment with >=2 biologic agents.
* Previous treatment with adalimumab or adalimumab biosimilar.
* Current treatment or previous treatment with leflunomide within 8 weeks.
* History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to adalimumab or any component of the trial drug.
* History of cancer including solid tumors, hematologic malignancies, and carcinoma in situ.
* Has evidence of positive serology for Hepatitis B virus or Hepatitis C virus
* Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit. Patients who are expecting to receive any live virus or bacterial vaccinations during the trial, or up to 3 months after the last dose of trial drug.
* Any treatment that, in the opinion of the investigator, may place the patient at unacceptable risk during the trial.
* Patients with a significant disease other than Rheumatoid arthritis and/or a significant uncontrolled disease (such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders). A significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial.
* Premenopausal, sexually active women who are pregnant or nursing, or are of child-bearing potential and not practicing an acceptable method of birth control, or do not plan to continue practicing an acceptable method of birth control throughout the trial.
* History of, or current, inflammatory joint disease other than Rheumatoid arthritis or other systemic autoimmune disorder.
* Diagnosis of juvenile idiopathic arthritis, and/or Rheumatoid arthritis before age 16.
* Any planned surgical procedure within 12 weeks prior to the Screening Visit or for the duration of the trial.
* Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with intravenous anti infectives within 4 weeks of the Screening Visit or completion of oral anti-infectives within 2 weeks of the Screening Visit.
* History of deep space/tissue infection within 52 weeks of the Screening Visit.
* History of serious infection or opportunistic infection in the last 2 years.
* Any neurological, vascular or systemic disorder that might affect any of the efficacy assessments.
* Currently active alcohol or drug abuse or history of alcohol or drug abuse within 2 years of the Screening Visit.
* Treatment with intravenous Gamma Globulin or the Prosorba® Column within 6 months of the Screening Visit.
* Treatment with intravenous, intramuscular, intra-articular and parenteral corticosteroids within 6 weeks prior to Day 1 or throughout the trial.
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times upper limit of normal.
* Hemoglobin <8.0 g/dL.
* Platelets <100,000/µL.
* Leukocyte count <4000/µL.
* Creatinine clearance <60 mL/min.
* Patients who are currently participating in another clinical trial or who have been participating in another clinical trial with another investigational drug within a minimum of 12 weeks or five half-lives (whichever is longer) of the drug prior to Day 1.
* Patients with a history of any clinically significant adverse reaction to murine or chimeric proteins.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/01/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
18/10/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
645
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Mississippi
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Montana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Mexico
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Virginia
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
Bulgaria
Query!
State/province [27]
0
0
Plovdiv
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Ruse
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Shumen
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Sofia
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Varna
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Veliko Tarnovo
Query!
Country [33]
0
0
Chile
Query!
State/province [33]
0
0
Osorno
Query!
Country [34]
0
0
Chile
Query!
State/province [34]
0
0
Puerto Varas
Query!
Country [35]
0
0
Chile
Query!
State/province [35]
0
0
Santiago
Query!
Country [36]
0
0
Chile
Query!
State/province [36]
0
0
Viña del Mar
Query!
Country [37]
0
0
Estonia
Query!
State/province [37]
0
0
Pärnu
Query!
Country [38]
0
0
Estonia
Query!
State/province [38]
0
0
Tartu
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Bad Doberan
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Bad Kreuznach
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Bad Nauheim
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Magdeburg
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szeged
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Veszprem
Query!
Country [45]
0
0
Korea, Republic of
Query!
State/province [45]
0
0
Daegu
Query!
Country [46]
0
0
Korea, Republic of
Query!
State/province [46]
0
0
Daejeon
Query!
Country [47]
0
0
Korea, Republic of
Query!
State/province [47]
0
0
Seoul
Query!
Country [48]
0
0
Malaysia
Query!
State/province [48]
0
0
Kuantan
Query!
Country [49]
0
0
Malaysia
Query!
State/province [49]
0
0
Pulau Pinang
Query!
Country [50]
0
0
New Zealand
Query!
State/province [50]
0
0
Cantebury
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Bialystok
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Bydgoszcz
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Elblag
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Gdynia
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Grodzisk Mazowiecki
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Katowice
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Krakow
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Torun
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Warszawa
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Wroclaw
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Kemerovo
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Moscow
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Petrozavodsk
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Samara
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Saratov
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Stavropol
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Yaroslavl
Query!
Country [68]
0
0
Serbia
Query!
State/province [68]
0
0
Belgrade
Query!
Country [69]
0
0
Serbia
Query!
State/province [69]
0
0
Niska Banja
Query!
Country [70]
0
0
Serbia
Query!
State/province [70]
0
0
Novi Sad
Query!
Country [71]
0
0
Serbia
Query!
State/province [71]
0
0
Sabac
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Barakaldo
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
La Coruña
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Santiago de Compostela
Query!
Country [76]
0
0
Thailand
Query!
State/province [76]
0
0
Bangkoknoi
Query!
Country [77]
0
0
Thailand
Query!
State/province [77]
0
0
Hat Yai
Query!
Country [78]
0
0
Thailand
Query!
State/province [78]
0
0
Rajathevee
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Ivano-Frankivsk
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Kharkiv
Query!
Country [81]
0
0
Ukraine
Query!
State/province [81]
0
0
Kyiv
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Poltava
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Vinnytsia
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Zaporizhzhia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective: The primary objective of this trial is to establish an equivalence in efficacy between BI 695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a statistical comparison of the proportion of patients meeting American College of Rheumatology 20% (ACR20) response rate at Week 12 and ACR20 response rate at Week 24 between BI 695501 and US-licensed Humira®. Secondary Objectives: The secondary objectives of this trial are to compare the efficacy, safety and immunogenicity of BI 695501 and US-licensed Humira® in patients with active RA including those undergoing the transition from US-licensed Humira® to BI 695501 after 24 weeks.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02137226
Query!
Trial related presentations / publications
Cohen SB, Lee EC. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis. Immunotherapy. 2022 Oct;14(15):1183-1190. doi: 10.2217/imt-2022-0106. Epub 2022 Sep 6. Huizinga TWJ, Torii Y, Muniz R. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatol Ther. 2021 Mar;8(1):41-61. doi: 10.1007/s40744-020-00259-8. Epub 2020 Dec 1. Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld KH. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Br J Clin Pharmacol. 2020 Nov;86(11):2274-2285. doi: 10.1111/bcp.14330. Epub 2020 Jun 11. Cohen SB, Alonso-Ruiz A, Klimiuk PA, Lee EC, Peter N, Sonderegger I, Assudani D. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018 Jun;77(6):914-921. doi: 10.1136/annrheumdis-2017-212245. Epub 2018 Mar 7.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02137226
Download to PDF